Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
about
Treating Negative Symptoms in Schizophrenia: an UpdateRole of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects.The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management.Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.Glutamatergic agents for schizophrenia: current evidence and perspectives.MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.Altering the course of schizophrenia: progress and perspectives.Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation.Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia.Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia.Toxoplasma gondii and schizophrenia: a review of published RCTs.Assessing brain immune activation in psychiatric disorders: clinical and preclinical PET imaging studies of the 18-kDa translocator protein.Maternal immune activation results in complex microglial transcriptome signature in the adult offspring that is reversed by minocycline treatment.A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review.Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: A historical cohort study.Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia.Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.Targeting the Immune System with Pharmacotherapy in Schizophrenia.A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.Anti-inflammatory effects of minocycline are mediated by retinoid signaling
P2860
Q26744805-449C1FE5-5AEE-4108-84C3-E9EBE81D58DFQ35591134-228A1155-7CA3-424D-BEF8-F845E79E33FAQ35819780-93B24626-92D7-4849-81EE-FC3EB141F675Q38402659-73CFAD52-9453-488C-87A7-5BDCEEF0DE98Q38444551-1A49D808-C689-45B1-888B-C3E716181900Q38622769-BF562C4A-E13E-42F7-BE16-0DF2C7C91BBFQ38647035-4D0932DB-452B-4E3F-997D-0EC16A671FBEQ38759421-1E311DE7-FD56-4BEF-871F-CE7381D8EC50Q38828405-6466B8CB-EEB9-43D4-8CB0-ABE87A1594BAQ38915253-65B02B14-E413-476F-9611-376BFD2AE20AQ38970065-1F5E2651-99A3-487B-B008-04E1685E8F20Q39050960-C1E5F0C6-6DD9-4231-ACE4-D3CE3661F42DQ39308979-24A25699-FB1B-4A8D-B56D-CE06EA02EB73Q40965410-4F8B7CFC-C3F2-479F-A757-D9EFF55417CBQ41173167-8A591BCE-DF5D-443C-B2A7-A85EE662492FQ45074171-4B93F6A7-CACE-4809-BF9C-39049FE88DC4Q47152736-54FF23D4-B80B-4C53-957B-1B8175BB37FAQ47352196-B2E7C9A8-71A8-4C63-A5F3-0F11FEF639F0Q47406216-5C40F392-785F-437C-94C0-C8460394A1E4Q47704592-5601C474-3A7B-402B-A6A5-EE34E57C6A0BQ47837511-A2ECE089-ED31-4D5B-A72B-E052B7CEFB32Q47861374-CC6231CC-C236-4FCC-B445-C9BDF19887A5Q58706730-B8E03896-2439-4679-A3D2-117B579BA3FB
P2860
Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and tolerability of m ...... randomized controlled trials.
@ast
Efficacy and tolerability of m ...... randomized controlled trials.
@en
Efficacy and tolerability of m ...... randomized controlled trials.
@nl
type
label
Efficacy and tolerability of m ...... randomized controlled trials.
@ast
Efficacy and tolerability of m ...... randomized controlled trials.
@en
Efficacy and tolerability of m ...... randomized controlled trials.
@nl
prefLabel
Efficacy and tolerability of m ...... randomized controlled trials.
@ast
Efficacy and tolerability of m ...... randomized controlled trials.
@en
Efficacy and tolerability of m ...... randomized controlled trials.
@nl
P2860
P356
P1476
Efficacy and tolerability of m ...... randomized controlled trials
@en
P2093
Kazuto Oya
Taro Kishi
P2860
P304
P356
10.1002/HUP.2426
P50
P577
2014-09-01T00:00:00Z